Sumitomo Dainippon Pharma Co., Ltd. provided financial guidance for the year ending March 31, 2023. For the period, the company expected Net sales of JPY 550,000 million, Operating profit of JPY 24,000 million, Net profit attributable to owners of parent of JPY 22,000 million and EPS of JPY 55.37.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
404 JPY | -0.74% |
|
-0.25% | -13.30% |
Jul. 02 | Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer | MT |
Jul. 02 | INOVIO Appointsof Steven Egge as Chief Commercial Officer | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.30% | 999M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2023